featured
First-Line Therapy for Type 2 Diabetes With SGLT2 Inhibitors and GLP-1 Receptor Agonists
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Internal Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study
Ann. Intern. Med 2022 Oct 04;[EPub Ahead of Print], JG Choi, AN Winn, MR Skandari, MI Franco, EM Staab, J Alexander, W Wan, M Zhu, ES Huang, L Philipson, N LaiteerapongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.